180 related articles for article (PubMed ID: 28650474)
1. An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.
Zimmermannova O; Doktorova E; Stuchly J; Kanderova V; Kuzilkova D; Strnad H; Starkova J; Alberich-Jorda M; Falkenburg JHF; Trka J; Petrak J; Zuna J; Zaliova M
Oncogene; 2017 Oct; 36(43):5985-5994. PubMed ID: 28650474
[TBL] [Abstract][Full Text] [Related]
2. Characterization of leukemias with ETV6-ABL1 fusion.
Zaliova M; Moorman AV; Cazzaniga G; Stanulla M; Harvey RC; Roberts KG; Heatley SL; Loh ML; Konopleva M; Chen IM; Zimmermannova O; Schwab C; Smith O; Mozziconacci MJ; Chabannon C; Kim M; Frederik Falkenburg JH; Norton A; Marshall K; Haas OA; Starkova J; Stuchly J; Hunger SP; White D; Mullighan CG; Willman CL; Stary J; Trka J; Zuna J
Haematologica; 2016 Sep; 101(9):1082-93. PubMed ID: 27229714
[TBL] [Abstract][Full Text] [Related]
3. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein.
Kawai H; Matsushita H; Suzuki R; Kitamura Y; Ogawa Y; Kawada H; Ando K
Neoplasia; 2019 Aug; 21(8):788-801. PubMed ID: 31276931
[TBL] [Abstract][Full Text] [Related]
6. A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Wagle M; Eiring AM; Wongchenko M; Lu S; Guan Y; Wang Y; Lackner M; Amler L; Hampton G; Deininger MW; O'Hare T; Yan Y
Leukemia; 2016 Jul; 30(7):1493-501. PubMed ID: 27044711
[TBL] [Abstract][Full Text] [Related]
7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
8. Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin.
Zuna J; Zaliova M; Muzikova K; Meyer C; Lizcova L; Zemanova Z; Brezinova J; Votava F; Marschalek R; Stary J; Trka J
Genes Chromosomes Cancer; 2010 Oct; 49(10):873-84. PubMed ID: 20589932
[TBL] [Abstract][Full Text] [Related]
9. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Moore FR; Yang F; Press RD
Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
[TBL] [Abstract][Full Text] [Related]
10. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
Jin W; Yun C; Hobbie A; Martin MJ; Sorensen PH; Kim SJ
Cancer Res; 2007 Apr; 67(7):3192-200. PubMed ID: 17409427
[TBL] [Abstract][Full Text] [Related]
11. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.
Piloto O; Wright M; Brown P; Kim KT; Levis M; Small D
Blood; 2007 Feb; 109(4):1643-52. PubMed ID: 17047150
[TBL] [Abstract][Full Text] [Related]
12. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia.
La Starza R; Trubia M; Testoni N; Ottaviani E; Belloni E; Crescenzi B; Martelli M; Flandrin G; Pelicci PG; Mecucci C
Haematologica; 2002 Aug; 87(8):789-94. PubMed ID: 12161353
[TBL] [Abstract][Full Text] [Related]
13. Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.
Baeumler J; Szuhai K; Falkenburg JH; van Schie ML; Ottmann OG; Nijmeijer BA
Cancer Genet Cytogenet; 2008 Aug; 185(1):37-42. PubMed ID: 18656692
[TBL] [Abstract][Full Text] [Related]
14. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.
Yoda A; Adelmant G; Tamburini J; Chapuy B; Shindoh N; Yoda Y; Weigert O; Kopp N; Wu SC; Kim SS; Liu H; Tivey T; Christie AL; Elpek KG; Card J; Gritsman K; Gotlib J; Deininger MW; Makishima H; Turley SJ; Javidi-Sharifi N; Maciejewski JP; Jaiswal S; Ebert BL; Rodig SJ; Tyner JW; Marto JA; Weinstock DM; Lane AA
Nat Med; 2015 Jan; 21(1):71-5. PubMed ID: 25485910
[TBL] [Abstract][Full Text] [Related]
15. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
16. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Schwaab J; Naumann N; Luebke J; Jawhar M; Somervaille TCP; Williams MS; Frewin R; Jost PJ; Lichtenegger FS; La Rosée P; Storch N; Haferlach T; Horny HP; Fabarius A; Haferlach C; Burchert A; Hofmann WK; Cross NCP; Hochhaus A; Reiter A; Metzgeroth G
Am J Hematol; 2020 Jul; 95(7):824-833. PubMed ID: 32279331
[TBL] [Abstract][Full Text] [Related]
17. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
Chiriches C; Khan D; Wieske M; Guillen N; Rokicki M; Guy C; Wilson M; Heesom KJ; Ottmann OG; Ruthardt M
Ann Hematol; 2022 Oct; 101(10):2179-2193. PubMed ID: 35941390
[TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative Neoplasm Driven by
Renzi S; Algawahmed F; Davidson S; Langenberg KPS; Fuligni F; Ali S; Anderson N; Brunga L; Bartram J; Abdelhaleem M; Naqvi A; Beimnet K; Schuh A; Tierens A; Malkin D; Shlien A; Shago M; Villani A
Curr Oncol; 2023 Jun; 30(7):5946-5952. PubMed ID: 37503586
[No Abstract] [Full Text] [Related]
19. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors.
Kiyota M; Kuroda J; Yamamoto-Sugitani M; Shimura Y; Nakayama R; Nagoshi H; Mizutani S; Chinen Y; Sasaki N; Sakamoto N; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
Apoptosis; 2013 Nov; 18(11):1437-1446. PubMed ID: 23851982
[TBL] [Abstract][Full Text] [Related]
20. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]